Search results for " antitumor"

showing 10 items of 416 documents

Antiproliferative activity against leukemia cells of sesquiterpene lactones from the Turkish endemic plant Centaurea drabifolia subsp. detonsa

2017

The apolar organic extract obtained from aerial parts of Centaurea drabifolia Sibth. & Sm. subsp. detonsa (Bornm.) Wagenitz, growing wild in Turkey, was investigated for the first time for its secondary metabolite composition. Seven sesquiterpene lactones belonging to the guaiane class (1-7), including the new compound 4, along with a fatty acid lactone derivative (8), were isolated. The structures of these compounds were established by spectroscopic analysis, including 2D NMR spectroscopic techniques, with the stereostructure of the new guaiane 4 determined with the help of MTPA derivatization. Cytotoxic activities of compounds 1-7 were evaluated against two cancer cell lines, namely acute…

TurkeyCentaurea drabifoliaStereochemistryCynaropicrinCentaureaMultidrug-resistant cell lineSecondary metaboliteBiologySesquiterpene01 natural sciencesLactonesSesquiterpenes GuaianeStructure-Activity Relationshipchemistry.chemical_compoundCell Line TumorDrug DiscoverymedicineHumansDerivatizationPharmacologychemistry.chemical_classificationLeukemiaMolecular StructurePlant Extracts010405 organic chemistryFatty acidGeneral MedicinePlant Components AerialAntineoplastic Agents PhytogenicCynaropicrin0104 chemical sciences010404 medicinal & biomolecular chemistrychemistryDrug Resistance NeoplasmAntileukemic activityDrug Screening Assays AntitumorSesquiterpene lactonesSesquiterpenesTwo-dimensional nuclear magnetic resonance spectroscopyDerivative (chemistry)Lactonemedicine.drugFitoterapia
researchProduct

Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.

2020

Abstract Progression on therapy in non-small cell lung carcinoma (NSCLC) is often evaluated radiographically, however, image-based evaluation of said therapies may not distinguish disease progression due to intrinsic tumor drug resistance or inefficient tumor penetration of the drugs. Here we report that the inhibition of mutated EGFR promotes the secretion of a potent vasoconstrictor, endothelin-1 (EDN1), which continues to increase as the cells become resistant with a mesenchymal phenotype. As EDN1 and its receptor (EDNR) is linked to cancer progression, EDNR-antagonists have been evaluated in several clinical trials with disappointing results. These trials were based on a hypothesis that…

Vascular Endothelial Growth Factor ACancer ResearchLung NeoplasmsAmbrisentanOncology and CarcinogenesisDrug ResistanceBiological AvailabilityAntineoplastic AgentsDrug resistanceCell LineMiceErlotinib HydrochlorideGefitinibIn vivomedicineAnimalsHumansOncology & CarcinogenesisNon-Small-Cell LungProtein Kinase InhibitorsLungCancerTumor microenvironmentTumorEndothelin-1business.industryCarcinomaLung CancerCancerEvaluation of treatments and therapeutic interventionsGefitinibmedicine.diseaseEndothelin 1Xenograft Model Antitumor AssaysErbB ReceptorsOncologyVasoconstriction5.1 Pharmaceuticals6.1 PharmaceuticalsCancer cellMutationCancer researchNeoplasmDevelopment of treatments and therapeutic interventionsbusinessmedicine.drug
researchProduct

VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cells

2014

Abstract Anti-VEGF therapy perturbs tumor metabolism, severely impairing oxygen, glucose, and ATP levels. In this study, we investigated the effects of anti-VEGF therapy in multiple experimental tumor models that differ in their glycolytic phenotypes to gain insights into optimal modulation of the metabolic features of this therapy. Prolonged treatments induced vascular regression and necrosis in tumor xenograft models, with highly glycolytic tumors becoming treatment resistant more rapidly than poorly glycolytic tumors. By PET imaging, prolonged treatments yielded an increase in both hypoxic and proliferative regions of tumors. A selection for highly glycolytic cells was noted and this met…

Vascular Endothelial Growth Factor ACancer ResearchPathologymedicine.medical_specialtyNecrosismedicine.medical_treatmentAngiogenesis InhibitorsMice SCIDBiologySCIDAntibodies Monoclonal HumanizedAntibodiesCell LineTargeted therapyMiceRandom AllocationCell Line TumorNeoplasmsMonoclonalAngiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Bevacizumab; Cell Line Tumor; Female; Glycolysis; Humans; MCF-7 Cells; Mice; Mice Inbred BALB C; Mice SCID; Molecular Targeted Therapy; Neoplasms; Phenotype; Random Allocation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor AssaysmedicineAnimalsHumansGlycolysisMolecular Targeted Therapycancer-cellAnti-VEGF therapyHumanizedInbred BALB CMED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAMice Inbred BALB CTumorpositron emission tomography antiangiogenesis glucose metabolism hypoxiaXenograft Model Antitumor AssaysPhenotypeBlockadeBevacizumabVascular endothelial growth factor APhenotypeOncologyCell cultureMonoclonalMCF-7 CellsCancer researchMED/06 - ONCOLOGIA MEDICAFemalemedicine.symptomGlycolysis
researchProduct

Increased basic fibroblast growth factor release and proliferation in xenotransplanted squamous cell carcinoma after combined irradiation/anti-vascul…

2012

Novel strategies of cancer therapy combine irradiation and anti-angiogenic active compounds. However, little is known concerning the undesired cellular and molecular effects caused by this novel treatment concept. We used a mouse squamous cell carcinoma (SCC) xenotransplantation model to evaluate the potential undesired effects which compromise the success of this therapeutic combination. SCCs were subcutanously implanted in nude mice. Animals were treated with a fractionated irradiation scheme (5x4 Gy) alone or in combination with daily injections of anti-vascular endothelial growth factor (VEGF) antibodies. Controls remained untreated. Before and after treatment, resonance imaging (MRI), …

Vascular Endothelial Growth Factor ACancer Researchmedicine.medical_treatmentBasic fibroblast growth factorMice NudeBiologychemistry.chemical_compoundMiceCell Line TumormedicineAnimalsHumansGrowth factor receptor inhibitorOncogeneGrowth factorHemodynamicsCancerGeneral MedicineCell cyclemedicine.diseaseMolecular medicineXenograft Model Antitumor AssaysOncologychemistryCancer researchCarcinoma Squamous CellFibroblast Growth Factor 2A431 cellsOncology reports
researchProduct

Synthesis of Combretastatin A-4 and 3′-Aminocombretastatin A-4 derivatives with Aminoacid Containing Pendants and Study of their Interaction with Tub…

2020

Natural product combretastatin A-4 (CA-4) and its nitrogenated analogue 3&prime

Vascular Endothelial Growth Factor ACell cycle checkpoint<i>htert</i>Pharmaceutical ScienceApoptosisAnalytical Chemistrychemistry.chemical_compound0302 clinical medicineDrug DiscoveryStilbenesc-<i>myc</i>Telomerase0303 health sciences<i>vegf</i>biologyNeovascularization PathologicChemistry3′-aminocombretastatin a-4Cell cycle<i>c-Myc</i>VEGFc-MycBiochemistryChemistry (miscellaneous)030220 oncology & carcinogenesisMCF-7 CellsMolecular Medicinecytotoxicitycell cyclehTERTHT29 CellsArticleProto-Oncogene Proteins c-mycmicrotubuleslcsh:QD241-44103 medical and health sciencesStructure-Activity Relationshiplcsh:Organic chemistryMicrotubuleCell Line TumorHumansPhysical and Theoretical Chemistry030304 developmental biologyCell ProliferationCombretastatinCombretastatin A-4Cell growthOrganic ChemistryAntineoplastic Agents PhytogenicTubulintubulinCell cultureA549 Cellsbiology.proteinM Phase Cell Cycle Checkpointscombretastatin a-4Drug Screening Assays AntitumorMolecules
researchProduct

Identification and optimization of small molecule antagonists of vasoactive intestinal peptide receptor-1 (VIPR1).

2012

Identification, synthesis and structure-activity relationship of small-molecule VIPR1 antagonists encompassing two chemical series are described.

Vasoactive intestinal peptide (VIP)Settore MED/09 - Medicina InternaReceptors Vasoactive Intestinal Polypeptide Type IClinical BiochemistryVasoactive intestinal peptidePharmaceutical ScienceAntineoplastic AgentsThiophenesBiochemistrySmall Molecule LibrariesStructure-Activity RelationshipCell Line TumorDrug DiscoveryStructure–activity relationshipHumansReceptorMolecular BiologyChemistryVasoactive intestinal peptide receptorOrganic ChemistryBiphenyl CompoundsSmall Molecule LibrariesSmall moleculeHigh-Throughput Screening AssaysBiochemistryCell cultureVasoactive intestinal peptide receptor (VIPR)Molecular MedicineDrug Screening Assays AntitumorVIPR1Bioorganicmedicinal chemistry letters
researchProduct

Composti a struttura ossazolica, procedimenti per la loro produzione e loro impiego per la cura di patologie a carattere iperproliferativo

2017

La presente invenzione riguarda composti che presentano nella loro struttura il sistema eterociclico [1,2]Ossazolo[5,4-e]isoindolo, un procedimento per la oro produzione e il loro impiego per la cura di patologie a carattere iperproliferativo comprese quelle di natura neoplastica. I nuovi derivati saggiati al National Cancer Institute di Bethesda su un 60 linee cellulari umane divise in 9 sottopannelli (mammella, ovaie, polmone, colon, SNC, melanoma, leucemia, rene, prostata), hanno mostrato attività antiproliferativa da micro a nanomolare, rivelando alcuni derivati particolarmente promettenti.

[12]Ossazolo]isoindoli agenti antitumoraliSettore CHIM/08 - Chimica Farmaceutica
researchProduct

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

2015

International audience; Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively evaluated. Since blastic plasmacytoid dendritic cell neoplasm cells express high levels of interleukin-3 receptor α chain (IL3-Rα or CD123), antitumor effects of the interleukin-3 receptor-targeted drug SL-401 against blastic plasmacytoid dendritic cell neoplasm were evaluated in vitro and in vivo. The cytotoxicity of SL-401 was assessed in patient-derived blastic plasmacytoid dendritic cell neoplasm cell lines (CAL-1 and …

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyMalePathology[SDV]Life Sciences [q-bio]ApoptosisMice SCIDMice0302 clinical medicineMice Inbred NODhemic and lymphatic diseasesTumor Cells CulturedMedicineCytotoxic T cellNeoplasm[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyCytotoxicityAged 80 and overmedicine.diagnostic_test[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyArticlesMiddle AgedFlow Cytometry3. Good health[SDV] Life Sciences [q-bio]030220 oncology & carcinogenesisHematologic NeoplasmsFemaleAdultmedicine.medical_specialtyRecombinant Fusion ProteinsBlotting WesternInterleukin-3 Receptor alpha Subunit[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologyIn Vitro TechniquesFlow cytometry03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerBiomarkers TumorAnimalsHumans[SDV.BC] Life Sciences [q-bio]/Cellular BiologyAgedCell ProliferationMyeloproliferative Disordersbusiness.industryCell growthDendritic Cellsmedicine.diseaseXenograft Model Antitumor Assaysstomatognathic diseasesCell cultureApoptosisCancer researchInterleukin-3 receptorbusiness030215 immunologyPlasmacytomaHaematologica
researchProduct

Chaperonopathies and chaperonotherapy. Hsp60 as therapeutic target in cancer: potential benefits and risks.

2013

In this minireview we focus on Hsp60 as a target for anticancer therapy. We discuss the new concepts of chaperonopathies and chaperonotherapy and present information on Hsp60 localization in the cell membrane of human tumor cells. We describe novel mechanisms for Hsp60 reaching the extracellular environment that involve membrane-associated stages, as well as data on anti-Hsp60 antibodies found in human sera, both in normal subjects and patients affected by autoimmune diseases. Finally, we discuss possible therapeutic applications of anti-Hsp60 antibodies in cancer treatment, evaluating also side effects on non-tumor cells. In conclusion, the way for investigating Hsp60-targeted anti-tumor t…

animal structuresCellchemical and pharmacologic phenomenaAntineoplastic AgentsBiologycomplex mixturesRisk AssessmentCell membraneDrug Delivery SystemsRisk FactorsNeoplasmsDrug DiscoverymedicineExtracellularAnimalsHumansSecretionPharmacologyMechanism (biology)fungiCancerChaperonin 60medicine.diseasemedicine.anatomical_structureImmunologybiology.proteinCancer researchHsp60 Cpn60 HSPD1 plasma membrane antibodies autoantibodies antitumor immunotherapy anticancer therapy chaperonopathies human sera.HSP60AntibodyCurrent pharmaceutical design
researchProduct

Dipeptides of S-Substituted Dehydrocysteine as Artzyme Building Blocks: Synthesis, Complexing Abilities and Antiproliferative Properties †

2021

Background: Dehydropeptides are analogs of peptides containing at least one conjugate double bond between α,β-carbon atoms. Its presence provides unique structural properties and reaction centre for chemical modification. In this study, the series of new class of dipeptides containing S-substituted dehydrocysteine with variety of heterocyclic moieties was prepared. The compounds were designed as the building blocks for the construction of artificial metalloenzymes (artzymes). Therefore, the complexing properties of representative compounds were also evaluated. Furthermore, the acknowledged biological activity of natural dehydropeptides was the reason to extend the study for antiproliferativ…

antiproliferative activityBALB 3T3 CellsDouble bondPotentiometric titrationSulforhodamine BTriazoleAntineoplastic Agents010402 general chemistry01 natural sciencesCatalysisArticlelcsh:ChemistryInorganic ChemistryMiceStructure-Activity Relationshipchemistry.chemical_compoundElimination reactionCell Line TumorAnimalsHumansChelationCysteinePhysical and Theoretical Chemistrydehydrocysteinelcsh:QH301-705.5Molecular BiologySpectroscopyCell Proliferationchemistry.chemical_classification010405 organic chemistryOrganic ChemistryChemical modificationDipeptidesGeneral MedicineHydrogen-Ion ConcentrationCombinatorial chemistryEnzymes0104 chemical sciencesComputer Science Applicationsdehydropeptideslcsh:Biology (General)lcsh:QD1-999chemistrycomplexing agentaddition-elimination reactionDrug Screening Assays AntitumorCopperConjugateInternational Journal of Molecular Sciences
researchProduct